CURLF vs USNA
Curaleaf Holdings, Inc. and Usana Health Sciences Inc., side by side — 5 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | CURLF | USNA |
|---|---|---|
| Revenue | $1.3B | $925.3M |
| Net income | $-231.1M | $10.8M |
| Gross margin | 49.8% | 78.3% |
| Net margin | −18.0% | 1.2% |
| Return on equity | −28.6% | 2.0% |
| Diluted EPS | −$0.35 | $0.58 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $74.3M | $8.5M |
| Equity | $756.4M | $533.1M |
| Net debt / equity | 0.59× | — |
| Current ratio | 1.52× | 2.24× |
| Revenue CAGR 5y | — | −4.0% |
| Profit CAGR 5y | — | −38.7% |
CURLF bills 1.4× the revenue of USNA, and CURLF closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Revenue by year
5 years side by side
| Fiscal year | CURLF | USNA |
|---|---|---|
| FY2025 | $1.3B | $925.3M |
| FY2024 | $1.3B | $854.5M |
| FY2023 | $1.3B | $921.0M |
| FY2022 | $1.3B | $998.6M |
| FY2021 | $1.2B | $1.2B |
Net income by year
Bottom line
| Fiscal year | CURLF | USNA |
|---|---|---|
| FY2025 | $-231.1M | $10.8M |
| FY2024 | $-215.4M | $42.0M |
| FY2023 | $-281.2M | $63.8M |
| FY2022 | $-370.1M | $69.3M |
| FY2021 | $-205.9M | $116.5M |
More in this industry